Overview of Thoracic Oncology Trials in Cooperative Groups Around the Globe

Ameen Abdulla Salahudeen; Manali I. Patel; Paul Baas; Walter J. Curran; Jeffrey D. Bradley; David R. Gandara; Glenwood D. Goss; Tony S. Mok; Suresh S. Ramalingam; Everett E. Vokes; Shakun M. Malik; Heather A. Wakelee

doi:10.1016/j.cllc.2016.06.007

Overview of Thoracic Oncology Trials in Cooperative Groups Around the Globe

Ameen Abdulla Salahudeen, Manali I. Patel, Paul Baas, Walter J. Curran, Jeffrey D. Bradley, David R. Gandara, Glenwood D. Goss, Tony S. Mok, Suresh S. Ramalingam, Everett E. Vokes, Shakun M. Malik, Heather A. Wakelee

Research output: Contribution to journal › Review article › peer-review

4 Scopus citations

Abstract

Survival rates of patients with either early and advanced stage non–small-cell lung cancer (NSCLC) have improved with newer systemic therapy and radiation techniques, including combination regimens, targeted therapies, and immunotherapies. The cancer cooperative groups have historically played a critical role in the advancement of NSCLC therapy. Annually, representatives from cooperative groups worldwide convene at the International Lung Cancer Congress (ILCC). In summer 2015, the ILCC reached its 16th anniversary. This article highlights the NSCLC studies presented by participating groups in 2015.

Original language	English
Pages (from-to)	5-12
Number of pages	8
Journal	Clinical Lung Cancer
Volume	18
Issue number	1
DOIs	https://doi.org/10.1016/j.cllc.2016.06.007
State	Published - Jan 1 2017

Keywords

Cooperative group
Mesothelioma
NCTN
NSCLC
SCLC

Access to Document

10.1016/j.cllc.2016.06.007

Cite this

@article{e247a49ae77e4a32b93f51f634c6949d,

title = "Overview of Thoracic Oncology Trials in Cooperative Groups Around the Globe",

abstract = "Survival rates of patients with either early and advanced stage non–small-cell lung cancer (NSCLC) have improved with newer systemic therapy and radiation techniques, including combination regimens, targeted therapies, and immunotherapies. The cancer cooperative groups have historically played a critical role in the advancement of NSCLC therapy. Annually, representatives from cooperative groups worldwide convene at the International Lung Cancer Congress (ILCC). In summer 2015, the ILCC reached its 16th anniversary. This article highlights the NSCLC studies presented by participating groups in 2015.",

keywords = "Cooperative group, Mesothelioma, NCTN, NSCLC, SCLC",

author = "Salahudeen, {Ameen Abdulla} and Patel, {Manali I.} and Paul Baas and Curran, {Walter J.} and Bradley, {Jeffrey D.} and Gandara, {David R.} and Goss, {Glenwood D.} and Mok, {Tony S.} and Ramalingam, {Suresh S.} and Vokes, {Everett E.} and Malik, {Shakun M.} and Wakelee, {Heather A.}",

note = "Publisher Copyright: {\textcopyright} 2016 Elsevier Inc.",

year = "2017",

month = jan,

day = "1",

doi = "10.1016/j.cllc.2016.06.007",

language = "English",

volume = "18",

pages = "5--12",

journal = "Clinical Lung Cancer",

issn = "1525-7304",

number = "1",

}

TY - JOUR

T1 - Overview of Thoracic Oncology Trials in Cooperative Groups Around the Globe

AU - Salahudeen, Ameen Abdulla

AU - Patel, Manali I.

AU - Baas, Paul

AU - Curran, Walter J.

AU - Bradley, Jeffrey D.

AU - Gandara, David R.

AU - Goss, Glenwood D.

AU - Mok, Tony S.

AU - Ramalingam, Suresh S.

AU - Vokes, Everett E.

AU - Malik, Shakun M.

AU - Wakelee, Heather A.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Survival rates of patients with either early and advanced stage non–small-cell lung cancer (NSCLC) have improved with newer systemic therapy and radiation techniques, including combination regimens, targeted therapies, and immunotherapies. The cancer cooperative groups have historically played a critical role in the advancement of NSCLC therapy. Annually, representatives from cooperative groups worldwide convene at the International Lung Cancer Congress (ILCC). In summer 2015, the ILCC reached its 16th anniversary. This article highlights the NSCLC studies presented by participating groups in 2015.

AB - Survival rates of patients with either early and advanced stage non–small-cell lung cancer (NSCLC) have improved with newer systemic therapy and radiation techniques, including combination regimens, targeted therapies, and immunotherapies. The cancer cooperative groups have historically played a critical role in the advancement of NSCLC therapy. Annually, representatives from cooperative groups worldwide convene at the International Lung Cancer Congress (ILCC). In summer 2015, the ILCC reached its 16th anniversary. This article highlights the NSCLC studies presented by participating groups in 2015.

KW - Cooperative group

KW - Mesothelioma

KW - NCTN

KW - NSCLC

KW - SCLC

UR - http://www.scopus.com/inward/record.url?scp=84997327244&partnerID=8YFLogxK

U2 - 10.1016/j.cllc.2016.06.007

DO - 10.1016/j.cllc.2016.06.007

M3 - Review article

C2 - 27473736

AN - SCOPUS:84997327244

SN - 1525-7304

VL - 18

SP - 5

EP - 12

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

IS - 1

ER -

Overview of Thoracic Oncology Trials in Cooperative Groups Around the Globe

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this